Trade on Pluang

One platform for all markets

Download

Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/MYQORZO® (aficamten) launches in Germany to treat obstructive hypertrophic cardiomyopathy, following EU approval.

CYTK

$76.97

+$0.21 +0.27%

MYQORZO® (aficamten) launches in Germany to treat obstructive hypertrophic cardiomyopathy, following EU approval.

Name: Pluang-Trading US Stock Crypto
Availability: InStock
Rating: 4.75 (118984 reviews)
Author: pluang

Company Fundamentals

01 Jun 2026

GlobeNewsWire

View Source

Bullish

Cytokinetics has launched MYQORZO® (aficamten) in Germany for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults, following its approval by the European Commission in February 2026. The drug, which inhibits cardiac myosin to reduce heart muscle obstruction, showed strong results in the Phase 3 SEQUOIA-HCM trial, improving exercise capacity and symptoms. MYQORZO was previously approved in the U.S. and China, and this European launch marks the start of broader availability in the region. This new treatment option offers hope for better symptom management in oHCM patients across Europe.

More News (CYTK)

Cytokinetics to present at major June healthcare investor conferences

Cytokinetics announced that its management team will participate in two key investor conferences in June 2026: the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs Global Healthcare Conference on June 8. These events will includ...

Market News

Neutral

4 days ago